NASDAQ:ABCL | Free Cash Flow | AbCellera Biologics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$33.52M$3.83M-$37.35M
2025-12-31-$34.74M$9.84M-$44.59M
2025-03-31-$11.55M$10.64M-$22.19M
2024-12-31-$8M$15.63M-$23.63M
2024-03-31-$41.71M$24.14M-$65.85M
2023-12-31-$19.61M$14.43M-$34.04M
2023-03-31-$44.06M$14.98M-$59.05M
2022-12-31$30.91M$12.33M$18.58M
2022-03-31$100.22M$14.5M$85.72M50.85%
2021-12-31-$16.71M$9.43M-$26.14M-43.61%
2021-03-31$109.55M$3.64M$105.9M90.34%
2020-12-31$1.28M$1.5M-$224,000.00-0.19%
2020-03-31-$764,000.00$583,000.00-$1.35M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$131.3M$42.77M-$174.07M
2024-12-31-$108.56M$78.4M-$186.95M
2023-12-31-$43.88M$76.95M-$120.82M
2022-12-31$277.36M$70.66M$206.7M130.39%
2021-12-31$244.58M$58.45M$186.13M121.29%
2020-12-31$22.69M$9.67M$13.02M10.95%
2019-12-31$2.69M$4M-$1.3M